Why we're focused on I&I
Chronic immuno-fibrotic diseases are among the most challenging conditions to treat. Despite multiple approved therapies, many patients experience lack of response, insufficient response, intolerance or loss of response, underscoring the complex biology and heterogeneity of these conditions. Precision medicine applied to I&I has the potential to address this urgent unmet need with therapies based on individual patient genetics and biology.
Now is the time for patient-first precision medicine
Precision medicine has revolutionized areas like oncology but has not been widely applied to immune-mediated and fibrotic diseases. Recent advances in human genetics, I&I and analytics provide better insights, creating new opportunities to deliver precision medicines that target the underlying biology of each patient’s disease.
We believe redefining patient care starts with precision, not convention
Mirador is defining precision medicine for I&I by leveraging breakthroughs in human genetics and cutting-edge data science to accelerate a first- and best-in-class pipeline with the potential to transform patient care. From our perspective, precision medicine is the power to:
Discover and validate novel targets
Genetics and multiomics enable causal insights into disease biology and drivers of disease, unlocking smarter target selection. Targets grounded in genetic and multiomic evidence have a higher probability of success in the clinic, reducing risk, accelerating development and improving patient outcomes.
Identify optimal drug combinations
Combinatorial biology uncovers synergistic pathways and drug combinations. The result: multispecific biologics and targeted drug combinations with the potential to deliver enhanced efficacy by addressing multiple disease drivers.
Match the right indication with the right target
Target prioritization grounded in genetics and multiomics is a key driver of indication selection. This evidence-based approach increases confidence in where a therapy will have the greatest clinical impact for patients.
Pinpoint patients most likely to benefit
Focus on genetically-associated targets fuels the development of diagnostics that pinpoint patients most likely to achieve a breakthrough response, enabling stratification of heterogeneous populations and more meaningful clinical benefit. The goal is to move beyond the trial-and-failure treatment cycle.
A transformative scientific approach
Mirador is advancing first- and best-in-class precision medicines to break through the efficacy ceiling that has constrained I&I treatments. At the core of our innovation is Mirador360™, our proprietary discovery and development engine designed to revolutionize drug design and power our pipeline.